AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda — BigGo Finance
AstraZeneca has terminated a late-stage clinical trial for its experimental bispecific antibody volrustomig in metastatic non-small cell lung…
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda
AstraZeneca has ended a Phase III trial of its bispecific volrustomig pitted against MSD’s blockbuster Keytruda (pembrolizumab) in…
From MRC discovery research to a one-minute cancer treatment | Innovate UK
While a one-minute treatment jab might sound simple, it represents the culmination of decades of Medical Research Council…